This article reviews the efficacy and tolerability of intravenous immunoglobulins (IVIg) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), including those forms associated with monoclonal gammopathy (paraproteinemic demyelinating neuropathy, PDN). Class I trials demonstrated that IVIg are effective in CIDP. About two-thirds of patients respond to initial treatment; however, most of them require repeated drug doses to maintain improvement. For PDN there are some evidences that IVIg are efficacious; however, it seems that less than 50% of the patients respond to this treatment and the persistence of the response over time has not been thoroughly investigated. The safety profile of immunoglobulins is generally good; however, the possibility of the occurrence of serious adverse effects should always be considered before starting treatment.
Mendeley saves you time finding and organizing research
Choose a citation style from the tabs below